{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:06:16Z","timestamp":1793804776022,"version":"4.6.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Central nervous system (CNS) involvement in adult acute lymphoblastic leukemia (ALL) remains a critical determinant of treatment failure and long-term survival. This review provides a comprehensive, evidence-based framework for the diagnosis, risk stratification, prophylaxis, and treatment of CNS disease in adult ALL, with emphasis on the evolving challenges introduced by immunotherapy-based and chemotherapy-sparing regimens and presents our institutional approach to CNS-directed therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Modern CNS prophylaxis combining intrathecal chemotherapy with CNS-penetrating systemic agents has dramatically reduced CNS relapse rates, yet diagnostic and therapeutic limitations persist. The increasing use of immunotherapies, such as blinatumomab and inotuzumab ozogamicin, has improved systemic disease control, while CNS relapse is increasingly recognized in this context, particularly among heavily pretreated patients. This pattern likely reflects multiple factors, including limited CNS penetration, improved disease control that unmasks previously subclinical CNS involvement, and the high-risk biology of relapsed\/refractory disease. In contrast, CD19-directed CAR T-cell therapies have demonstrated meaningful activity in CNS disease, while investigational strategies targeting leukemic trafficking pathways and IL-15 signaling offer additional preclinical promise.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>As adult ALL treatment has shifted toward chemotherapy-sparing regimens, new concerns have emerged regarding disease control within the CNS compartment. Durable remission will require integration of rigorous intrathecal prophylaxis, risk-adapted systemic therapy, and novel agents capable of penetrating the CNS microenvironment into every treatment algorithm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11899-026-00782-5","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:19:15Z","timestamp":1783909155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Breaching the Blood-Brain Barrier: Evolving Strategies for Central Nervous System Disease in Adult Acute Lymphoblastic Leukemia"],"prefix":"10.1007","volume":"21","author":[{"given":"Liesl S.","family":"Eibschutz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Tatum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"2","key":"782_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1055\/s-0041-1730752","volume":"13","author":"MS Tevatia","year":"2021","unstructured":"Tevatia MS, Sharma I, Jadhav T, Somasundaram V, Sharma S. Isolated CNS Relapse in Acute Lymphoblastic Leukemia (ALL): An Experience from a Tertiary Care Center. J Lab Physicians. 2021;13(2):134\u20138. https:\/\/doi.org\/10.1055\/s-0041-1730752.","journal-title":"J Lab Physicians"},{"issue":"3","key":"782_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/BS9.0000000000000162","volume":"5","author":"S Liu","year":"2023","unstructured":"Liu S, Wang Y. Diagnosis and management of adult central nervous system leukemia. Blood Sci. 2023;5(3):141\u20139. https:\/\/doi.org\/10.1097\/BS9.0000000000000162. Published 2023 May 30.","journal-title":"Blood Sci"},{"key":"782_CR3","doi-asserted-by":"publisher","unstructured":"Del Principe MI, Maurillo L, Buccisano F, et al. Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy. Mediterr J Hematol Infect Dis. 2014;6(1):e2014075. https:\/\/doi.org\/10.4084\/MJHID.2014.075. Published 2014 Nov 1.","DOI":"10.4084\/MJHID.2014.075"},{"key":"782_CR4","doi-asserted-by":"publisher","unstructured":"Hu Z. E S. Challenges and Advances in the Detection of Leukemic Blasts in Cerebrospinal Fluid in Pediatric Acute Lymphoblastic Leukemia. Cancers (Basel). 2026;18(5):840. Published 2026 Mar 5. https:\/\/doi.org\/10.3390\/cancers18050840","DOI":"10.3390\/cancers18050840"},{"key":"782_CR5","unstructured":"Acute Lymphoblastic Leukemia. National Comprehensive Cancer Network. Updated 2025-06-27."},{"issue":"6","key":"782_CR6","doi-asserted-by":"publisher","first-page":"e1903","DOI":"10.1093\/cid\/ciaa777","volume":"73","author":"R Hasbun","year":"2021","unstructured":"Hasbun R, van de Beek D, Brouwer MC, Bewley J, Bhimraj A, Bhatt DL, et al. Consensus guidelines for lumbar puncture in patients with neurological diseases. Clin Infect Dis. 2021;73(6):e1903\u201314. https:\/\/doi.org\/10.1093\/cid\/ciaa777.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"782_CR7","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2214\/AJR.16.16221","volume":"207","author":"JP Guenette","year":"2016","unstructured":"Guenette JP, Tirumani SH, Keraliya AR, Shinagare AB, Ramaiya NH, Jagannathan JP. MRI Findings in Patients With Leukemia and Positive CSF Cytology: A Single-Institution 5-Year Experience. AJR Am J Roentgenol. 2016;207(6):1278\u201382. https:\/\/doi.org\/10.2214\/AJR.16.16221.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"782_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ana.410380111","volume":"38","author":"RJ Freilich","year":"1995","unstructured":"Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38(1):51\u20137. https:\/\/doi.org\/10.1002\/ana.410380111.","journal-title":"Ann Neurol"},{"issue":"22","key":"782_CR9","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.2016.71.4774","volume":"35","author":"N Winick","year":"2017","unstructured":"Winick N, Devidas M, Chen S, et al. Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children\u2019s Oncology Group. J Clin Oncol. 2017;35(22):2527\u201334. https:\/\/doi.org\/10.1200\/JCO.2016.71.4774.","journal-title":"J Clin Oncol"},{"issue":"3","key":"782_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.hgmx.2015.05.004","volume":"78","author":"G Barranco-Lamp\u00f3n","year":"2015","unstructured":"Barranco-Lamp\u00f3n G, Rozen-Fuller E, Olarte-Carrilo I, Mart\u00ednez-Tovar A, Le\u00f3n-Gonz\u00e1lez G, Castellanos-Sinco H, et al. Association between traumatic lumbar puncture and the risk of central nervous system relapse in adults with acute lymphoblastic leukaemia. Rev Med Hosp Gen Mex. 2015;78(3):124\u20138. https:\/\/doi.org\/10.1016\/j.hgmx.2015.05.004.","journal-title":"Rev Med Hosp Gen Mex"},{"issue":"7","key":"782_CR11","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.3109\/10428194.2013.852667","volume":"55","author":"Z Mitri","year":"2014","unstructured":"Mitri Z, Siddiqui MT, El Rassi F, et al. Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia\/lymphoma. Leuk Lymphoma. 2014;55(7):1498\u2013500. https:\/\/doi.org\/10.3109\/10428194.2013.852667.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"782_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3324\/haematol.2019.231704","volume":"106","author":"MI Del Principe","year":"2021","unstructured":"Del Principe MI, Buzzatti E, Piciocchi A, et al. Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network. Haematologica. 2021;106(1):39\u201345. https:\/\/doi.org\/10.3324\/haematol.2019.231704. Published 2021 Jan 1.","journal-title":"Haematologica"},{"issue":"4","key":"782_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjh.18537","volume":"200","author":"M Dargenio","year":"2023","unstructured":"Dargenio M, Bonifacio M, Chiaretti S, et al. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study. Br J Haematol. 2023;200(4):440\u201350. https:\/\/doi.org\/10.1111\/bjh.18537.","journal-title":"Br J Haematol"},{"issue":"1","key":"782_CR14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/asheducation-2016.1.573","volume":"2016","author":"N G\u00f6kbuget","year":"2016","unstructured":"G\u00f6kbuget N. Treatment of older patients with acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016;2016(1):573\u20139. https:\/\/doi.org\/10.1182\/asheducation-2016.1.573.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"12","key":"782_CR15","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1002\/cncr.21948","volume":"106","author":"JM Sancho","year":"2006","unstructured":"Sancho JM, Ribera JM, Oriol A, et al. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer. 2006;106(12):2540\u20136. https:\/\/doi.org\/10.1002\/cncr.21948.","journal-title":"Cancer"},{"issue":"19","key":"782_CR16","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2023020794","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1891\u2013902. https:\/\/doi.org\/10.1182\/blood.2023020794.","journal-title":"Blood"},{"issue":"5","key":"782_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s11912-012-0247-7","volume":"14","author":"T Liu-Dumlao","year":"2012","unstructured":"Liu-Dumlao T, Kantarjian H, Thomas DA, O\u2019Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep. 2012;14(5):387\u201394. https:\/\/doi.org\/10.1007\/s11912-012-0247-7.","journal-title":"Curr Oncol Rep"},{"issue":"19","key":"782_CR18","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","volume":"130","author":"SK Tasian","year":"2017","unstructured":"Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia. Blood. 2017;130(19):2064\u201372. https:\/\/doi.org\/10.1182\/blood-2017-06-743252.","journal-title":"Blood"},{"issue":"10506","key":"782_CR19","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","volume":"406","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Pui CH, Jabbour E. Acute lymphocytic leukaemia. Lancet. 2025;406(10506):950\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(25)00864-5.","journal-title":"Lancet"},{"key":"782_CR20","unstructured":"ASH Clinical Practice Guidelines on Acute Lymphoblastic Leukemia in Adolescents and Young Adults. American Society of Hematology. (2024). 2024."},{"issue":"6","key":"782_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3324\/haematol.2014.123273","volume":"100","author":"R Bassan","year":"2015","unstructured":"Bassan R, Masciulli A, Intermesoli T, et al. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. Haematologica. 2015;100(6):786\u201393. https:\/\/doi.org\/10.3324\/haematol.2014.123273.","journal-title":"Haematologica"},{"issue":"8","key":"782_CR22","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2006-08-043646","volume":"109","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, O\u2019Brien S, Kantarjian H, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109(8):3214\u20138. https:\/\/doi.org\/10.1182\/blood-2006-08-043646.","journal-title":"Blood"},{"issue":"2","key":"782_CR23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.1987.5.2.202","volume":"5","author":"FM Balis","year":"1987","unstructured":"Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5(2):202\u20137. https:\/\/doi.org\/10.1200\/JCO.1987.5.2.202.","journal-title":"J Clin Oncol"},{"issue":"6","key":"782_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1365-2141.2005.05509.x","volume":"129","author":"CD Mitchell","year":"2005","unstructured":"Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol. 2005;129(6):734\u201345. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05509.x.","journal-title":"Br J Haematol"},{"issue":"9","key":"782_CR25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3324\/haematol.2009.018580","volume":"95","author":"B Labar","year":"2010","unstructured":"Labar B, Suciu S, Willemze R, et al. Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica. 2010;95(9):1489\u201395. https:\/\/doi.org\/10.3324\/haematol.2009.018580.","journal-title":"Haematologica"},{"issue":"n01","key":"782_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7399\/fh.2017.41.1.10616","volume":"41","author":"R Olmos-Jim\u00e9nez","year":"2017","unstructured":"Olmos-Jim\u00e9nez R, Espuny-Mir\u00f3 A, C\u00e1rceles Rodr\u00edguez C, D\u00edaz-Carrasco MS. Practical aspects of the use of intrathecal chemotherapy. Aspectos pr\u00e1cticos de la utilizaci\u00f3n de quimioterapia intratecal. Farm Hosp. 2017;41(n01):105\u201329. https:\/\/doi.org\/10.7399\/fh.2017.41.1.10616. Published 2017 Jan 1.","journal-title":"Farm Hosp"},{"issue":"4","key":"782_CR27","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3390\/cancers14040902","volume":"14","author":"M Van Trimpont","year":"2022","unstructured":"Van Trimpont M, Peeters E, De Visser Y, et al. Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy. Cancers (Basel). 2022;14(4):902. https:\/\/doi.org\/10.3390\/cancers14040902. Published 2022 Feb 11.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"782_CR28","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1182\/blood.2022017035","volume":"141","author":"NE Kopmar","year":"2023","unstructured":"Kopmar NE, Cassaday RD. How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia. Blood. 2023;141(12):1379\u201388. https:\/\/doi.org\/10.1182\/blood.2022017035.","journal-title":"Blood"},{"key":"782_CR29","doi-asserted-by":"crossref","unstructured":"Jabbour E, Thomas D, Cortes J, Kantarjian H, O\u2019Brien S. Central Nervous System Prophylaxis in Adults with Acute Lymphoblastic Leukemia. Cancer. 2010.","DOI":"10.1002\/cncr.25008"},{"key":"782_CR30","unstructured":"Garcia-Manero G, Kantarjian HM, Schiffer CA et al. Central Nervous System Prophylaxis and Therapy. In: Kufe DW, Pollock RE, Weichselbaum RR, editors. Holland-F1rei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003."},{"key":"782_CR31","doi-asserted-by":"crossref","unstructured":"Thomas DA, O\u2019Brien S, Rytting M, Ravandi F, Jabbour E, Ferrajoli A, et al. Incidence of central nervous system (CNS) relapse in de novo adult acute lymphoblastic leukemia (ALL). Blood. 2014 Dec;6(21):940\u2013940. [cited 2022 Oct 1].","DOI":"10.1182\/blood.V124.21.940.940"},{"issue":"11","key":"782_CR32","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.leukres.2008.04.011","volume":"32","author":"O Reman","year":"2008","unstructured":"Reman O, Pigneux A, Huguet F, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and\/or at first relapse: results from the GET-LALA group. Leuk Res. 2008;32(11):1741\u201350. https:\/\/doi.org\/10.1016\/j.leukres.2008.04.011.","journal-title":"Leuk Res"},{"issue":"12","key":"782_CR33","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s11864-022-01032-5","volume":"23","author":"SY Wu","year":"2022","unstructured":"Wu SY, Short NJ, Nasr L, Dabaja BS, Fang PQ. Central Nervous System Prophylaxis and Treatment in Acute Leukemias. Curr Treat Options Oncol. 2022;23(12):1829\u201344. https:\/\/doi.org\/10.1007\/s11864-022-01032-5.","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"782_CR34","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","volume":"11","author":"S Pagliuca","year":"2024","unstructured":"Pagliuca S, Schmid C, Santoro N, et al. Donor lymphocyte infusion after allogeneic hematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. Lancet Haematol. 2024;11(6):e448\u201358. https:\/\/doi.org\/10.1016\/S2352-3026(24)00098-X.","journal-title":"Lancet Haematol"},{"issue":"9","key":"782_CR35","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41409-025-02639-6","volume":"60","author":"D Kwag","year":"2025","unstructured":"Kwag D, Yoon JH, Min GJ, et al. Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new immunotherapeutic agents. Bone Marrow Transpl. 2025;60(9):1249\u201357. https:\/\/doi.org\/10.1038\/s41409-025-02639-6.","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"782_CR36","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjh.15973","volume":"186","author":"A Nagler","year":"2019","unstructured":"Nagler A, Labopin M, Dholaria B, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019;186(5):767\u201376. https:\/\/doi.org\/10.1111\/bjh.15973.","journal-title":"Br J Haematol"},{"issue":"1","key":"782_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1182\/hematology.2025000711","volume":"2025","author":"RD Cassaday","year":"2025","unstructured":"Cassaday RD. Sanctuary sites and extramedullary relapses in the chemo-free world: insights from immunotherapies in B-ALL. Hematol Am Soc Hematol Educ Program. 2025;2025(1):245\u201351. https:\/\/doi.org\/10.1182\/hematology.2025000711.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"782_CR38","unstructured":"BLINCYTO. FDA Drug Label. Food and Drug Administration. Updated date: 2025-10-21."},{"issue":"1","key":"782_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/bjh.20134","volume":"207","author":"AC Wilke","year":"2025","unstructured":"Wilke AC, G\u00f6kbuget N. The role of blinatumomab in adult acute B lymphoblastic leukaemia. Br J Haematol. 2025;207(1):27\u201342. https:\/\/doi.org\/10.1111\/bjh.20134.","journal-title":"Br J Haematol"},{"issue":"3","key":"782_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/cncr.33967","volume":"128","author":"I Aldoss","year":"2022","unstructured":"Aldoss I, Otoukesh S, Zhang J, et al. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. Cancer. 2022;128(3):529\u201335. https:\/\/doi.org\/10.1002\/cncr.33967.","journal-title":"Cancer"},{"issue":"14","key":"782_CR41","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474\u201387. https:\/\/doi.org\/10.1002\/cncr.32116.","journal-title":"Cancer"},{"issue":"6","key":"782_CR42","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cncr.33321","volume":"127","author":"W Stock","year":"2021","unstructured":"Stock W, Martinelli G, Stelljes M, et al. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed\/refractory acute lymphoblastic leukemia. Cancer. 2021;127(6):905\u201313. https:\/\/doi.org\/10.1002\/cncr.33321.","journal-title":"Cancer"},{"issue":"6","key":"782_CR43","doi-asserted-by":"publisher","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Senapati J, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023;10(6):e433\u201344. https:\/\/doi.org\/10.1016\/S2352-3026(23)00073-X.","journal-title":"Lancet Haematol"},{"issue":"Suppl","key":"782_CR44","doi-asserted-by":"publisher","first-page":"e67564ca","DOI":"10.1097\/01.HS9.0000968344.67564.ca","volume":"7","author":"N Short","year":"2023","unstructured":"Short N, Jabbour E, Jain N, et al. P358: Hyper-Cvad With Blinatumomab And Inotuzumab Ozogamicin For Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: A Phase Ii Study. Hemasphere. 2023;7(Suppl):e67564ca. https:\/\/doi.org\/10.1097\/01.HS9.0000968344.67564.ca. Published 2023 Aug 8.","journal-title":"Hemasphere"},{"issue":"23","key":"782_CR45","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood.2021013733","volume":"139","author":"Y Qi","year":"2022","unstructured":"Qi Y, Zhao M, Hu Y, et al. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood. 2022;139(23):3376\u201386. https:\/\/doi.org\/10.1182\/blood.2021013733.","journal-title":"Blood"},{"issue":"10299","key":"782_CR46","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8.","journal-title":"Lancet"},{"issue":"5","key":"782_CR47","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","volume":"39","author":"BD Shah","year":"2025","unstructured":"Shah BD, Cassaday RD, Park JH, et al. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025;39(5):1058\u201368. https:\/\/doi.org\/10.1038\/s41375-025-02532-7.","journal-title":"Leukemia"},{"issue":"16","key":"782_CR48","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1182\/bloodadvances.2024015779","volume":"9","author":"IN Muhsen","year":"2025","unstructured":"Muhsen IN, Roloff GW, Faramand R, et al. Outcomes of brexucabtagene autoleucel in patients with relapsed\/refractory acute lymphoblastic leukemia with CNS involvement. Blood Adv. 2025;9(16):4081\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2024015779.","journal-title":"Blood Adv"},{"key":"782_CR49","first-page":"196","volume":"5","author":"LM Secker-Walker","year":"1991","unstructured":"Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia. 1991;5:196\u20139.","journal-title":"Leukemia"},{"issue":"5","key":"782_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.clml.2023.12.007","volume":"24","author":"FG Haddad","year":"2024","unstructured":"Haddad FG, Jabbour E, Short NJ, Jain N, Kantarjian H. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024;24(5):271\u20136. https:\/\/doi.org\/10.1016\/j.clml.2023.12.007.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"782_CR51","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/hematology.2022000413","volume":"2022","author":"FG Haddad","year":"2022","unstructured":"Haddad FG, Short NJ. Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia? Hematol Am Soc Hematol Educ Program. 2022;2022(1):213\u20137. https:\/\/doi.org\/10.1182\/hematology.2022000413.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"782_CR52","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","volume":"112","author":"K Porkka","year":"2008","unstructured":"Porkka K, Koskenvesa P, Lund\u00e1n T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112(4):1005\u201312. https:\/\/doi.org\/10.1182\/blood-2008-02-140665.","journal-title":"Blood"},{"issue":"1","key":"782_CR53","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s12185-025-04058-1","volume":"123","author":"S Nishiwaki","year":"2026","unstructured":"Nishiwaki S, Sugiura I, Fujisawa S, et al. Dasatinib is superior to imatinib in adult Ph\u2009+\u2009ALL: a propensity score-matched analysis of pooled JALSG trial data. Int J Hematol. 2026;123(1):24\u201331. https:\/\/doi.org\/10.1007\/s12185-025-04058-1.","journal-title":"Int J Hematol"},{"issue":"Suppl","key":"782_CR54","doi-asserted-by":"publisher","first-page":"e68516d0","DOI":"10.1097\/01.HS9.0000967352.68516.d0","volume":"7","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Kantarjian H, Aldoss I, et al. S110: Phallcon: A Phase 3 Study Comparing Ponatinib Versus Imatinib In Newly Diagnosed Ph\u2009+\u2009All. Hemasphere. 2023;7(Suppl):e68516d0. https:\/\/doi.org\/10.1097\/01.HS9.0000967352.68516.d0. Published 8 Aug 2023.","journal-title":"Hemasphere"},{"issue":"8","key":"782_CR55","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1080\/10428194.2021.1894647","volume":"62","author":"K Ravi","year":"2021","unstructured":"Ravi K, Franson A, Homan MJ, et al. Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. Leuk Lymphoma. 2021;62(8):1990\u20134. https:\/\/doi.org\/10.1080\/10428194.2021.1894647.","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"782_CR56","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-24-1086","volume":"30","author":"GE Pamuk","year":"2024","unstructured":"Pamuk GE, Chow ECY, Ionan AC, et al. FDA Approval Summary: Asciminib for Ph\u2009+\u2009CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation. Clin Cancer Res. 2024;30(19):4266\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1086.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"782_CR57","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1182\/blood.2024027064","volume":"145","author":"F Lang","year":"2025","unstructured":"Lang F, Ottmann OG. Asciminib for Ph\u2009+\u2009ALL: a step forward? Blood. 2025;145(6):551\u20132. https:\/\/doi.org\/10.1182\/blood.2024027064.","journal-title":"Blood"},{"issue":"4","key":"782_CR58","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide CA, Zabriskie MS, Savage Stevens SL, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. 2019;36(4):431\u2013e4435. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.004.","journal-title":"Cancer Cell"},{"key":"782_CR59","unstructured":"Scemblix (asciminib). FDA Drug Label. Food and Drug Administration. Updated date: 2024-10-29."},{"issue":"4","key":"782_CR60","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","volume":"29","author":"I Aldoss","year":"2023","unstructured":"Aldoss I, Khaled SK, Wang X, et al. Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed\/Refractory ALL. Clin Cancer Res. 2023;29(4):742\u201353. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2038.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"782_CR61","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1186\/s12967-025-06608-x","volume":"23","author":"B He","year":"2025","unstructured":"He B, Lin R, Xu N, et al. Efficacy and safety of third-generation CD19-CAR T cells incorporating CD28 and TLR2 intracellular domains for B-cell malignancies with central nervous system involvement: results of a pivotal trial. J Transl Med. 2025;23(1):594. https:\/\/doi.org\/10.1186\/s12967-025-06608-x. Published 2025 May 27.","journal-title":"J Transl Med"},{"issue":"4","key":"782_CR62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","volume":"9","author":"G de Oliveira Canedo","year":"2025","unstructured":"de Oliveira Canedo G, Roddie C, Amrolia PJ. Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. Blood Adv. 2025;9(4):704\u201321. https:\/\/doi.org\/10.1182\/bloodadvances.2024013586.","journal-title":"Blood Adv"},{"issue":"7716","key":"782_CR63","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41586-018-0342-5","volume":"560","author":"H Yao","year":"2018","unstructured":"Yao H, Price TT, Cantelli G, et al. Leukaemia hijacks a neural mechanism to invade the central nervous system. Nature. 2018;560(7716):55\u201360. https:\/\/doi.org\/10.1038\/s41586-018-0342-5.","journal-title":"Nature"},{"issue":"2","key":"782_CR64","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.2019001417","volume":"136","author":"EJ Gang","year":"2020","unstructured":"Gang EJ, Kim HN, Hsieh YT, et al. Integrin \u03b16 mediates the drug resistance of acute lymphoblastic B-cell leukemia. Blood. 2020;136(2):210\u201323. https:\/\/doi.org\/10.1182\/blood.2019001417.","journal-title":"Blood"},{"issue":"5","key":"782_CR65","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1182\/blood-2017-03-769315","volume":"130","author":"V M\u00fcnch","year":"2017","unstructured":"M\u00fcnch V, Trentin L, Herzig J, et al. Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor. Blood. 2017;130(5):643\u201354. https:\/\/doi.org\/10.1182\/blood-2017-03-769315.","journal-title":"Blood"},{"issue":"16","key":"782_CR66","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood.2024024952","volume":"144","author":"H Srinagesh","year":"2024","unstructured":"Srinagesh H, Jackson C, Shiraz P, et al. A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia. Blood. 2024;144(16):1689\u201398. https:\/\/doi.org\/10.1182\/blood.2024024952.","journal-title":"Blood"},{"issue":"1","key":"782_CR67","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","volume":"2016","author":"EA Raetz","year":"2016","unstructured":"Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2016;2016(1):580\u20138. https:\/\/doi.org\/10.1182\/asheducation-2016.1.580.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"782_CR68","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41375-025-02529-2","volume":"39","author":"FM Hormann","year":"2025","unstructured":"Hormann FM, Rudd SG. Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action. Leukemia. 2025;39(3):531\u201342. https:\/\/doi.org\/10.1038\/s41375-025-02529-2.","journal-title":"Leukemia"},{"key":"782_CR69","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1038\/s41375-024-02414-4","volume":"38","author":"F Ravandi","year":"2024","unstructured":"Ravandi F, Senapati J, Jain N, et al. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia. 2024;38:2717\u201321. https:\/\/doi.org\/10.1038\/s41375-024-02414-4.","journal-title":"Leukemia"},{"issue":"3","key":"782_CR70","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","volume":"9","author":"MR Luskin","year":"2025","unstructured":"Luskin MR, Shimony S, Keating J, et al. Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025;9(3):617\u201326. https:\/\/doi.org\/10.1182\/bloodadvances.2024014405.","journal-title":"Blood Adv"},{"issue":"12","key":"782_CR71","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/ajh.27094","volume":"98","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yang J, Li J, et al. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. Am J Hematol. 2023;98(12):1898\u2013908. https:\/\/doi.org\/10.1002\/ajh.27094.","journal-title":"Am J Hematol"},{"issue":"2","key":"782_CR72","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1056\/NEJMoa2505478","volume":"394","author":"R Chiesa","year":"2026","unstructured":"Chiesa R, Georgiadis C, Rashed H, et al. Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2026;394(2):152\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2505478.","journal-title":"N Engl J Med"},{"key":"782_CR73","doi-asserted-by":"publisher","unstructured":"Bruzzese A, Vigna E, Martino EA, et al. Ph-Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs. Eur J Haematol Published online March. 2026;15. https:\/\/doi.org\/10.1111\/ejh.70169.","DOI":"10.1111\/ejh.70169"},{"issue":"32","key":"782_CR74","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1200\/JCO-25-00307","volume":"43","author":"MJ Wieduwilt","year":"2025","unstructured":"Wieduwilt MJ, Yin J, Kour O, et al. Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results. J Clin Oncol. 2025;43(32):3526\u201335. https:\/\/doi.org\/10.1200\/JCO-25-00307.","journal-title":"J Clin Oncol"},{"issue":"6","key":"782_CR75","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3390\/cancers16061208","volume":"16","author":"J Laniel","year":"2024","unstructured":"Laniel J, Sultan S, Sinnett D, et al. Cumulative Dosage of Intrathecal Chemotherapy Agents Predicts White Matter Integrity in Long-Term Survivors of Acute Lymphoblastic Leukemia: A PETALE Study. Cancers (Basel). 2024;16(6):1208. https:\/\/doi.org\/10.3390\/cancers16061208. Published 2024 Mar 19.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"782_CR76","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S1474-4422(10)70220-9","volume":"9","author":"M Khasraw","year":"2010","unstructured":"Khasraw M, Posner JB. Neurological complications of systemic cancer. Lancet Neurol. 2010;9(12):1214\u201327. https:\/\/doi.org\/10.1016\/S1474-4422(10)70220-9.","journal-title":"Lancet Neurol"},{"issue":"2","key":"782_CR77","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/bjh.20200","volume":"207","author":"J Tinajero","year":"2025","unstructured":"Tinajero J, Ngo D, Motta M, et al. The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission. Br J Haematol. 2025;207(2):426\u201331. https:\/\/doi.org\/10.1111\/bjh.20200.","journal-title":"Br J Haematol"},{"issue":"Supplement1","key":"782_CR78","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1182\/blood-2019-129657","volume":"134","author":"G Richard-Carpentier","year":"2019","unstructured":"Richard-Carpentier G, Kantarjian HM, Short NJ, Jabbour E. Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. 2019;134(Supplement1):3807. https:\/\/doi.org\/10.1182\/blood-2019-129657.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00782-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00782-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00782-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:19:18Z","timestamp":1783909158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00782-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00782-5","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Liesl Eibschutz, Samuel Crow, Caroline Tatum, Daniel Reed, and Michael Keng declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}